Quantcast

Latest Biologic Stories

2014-10-22 20:23:26

Launches discussion about the future of biosimilars in Italy ROME, Oct. 22, 2014 /PRNewswire/ -- Results from a survey of 470 European physicians conducted by the Alliance for Safe Biologic Medicines (ASBM) set the stage for a stakeholder meeting at the Italian Ministry of Health to discuss the future of biosimilars policy in Italy. The October 20(th) event, titled "Biosimilars in Clinical Practice: Does Italy Need to Act?" included regulators from the Italian Medicines Agency...

2014-10-21 23:05:40

Dr. David Rabuka, Catalent Pharma Solutions’ Global Head of R&D Chemical Biology, is to present “Site Specific Antibody Drug Conjugate (ADC) Generation using SMARTag™ Technology” at the forthcoming World ADC Congress, which takes place from 26th to 29th October 2014, at the San Diego Marriott Marquis Hotel, San Diego, California. Somerset, N.J. (PRWEB) October 21, 2014 Dr. David Rabuka, Catalent Pharma Solutions’ Global Head of R&D Chemical Biology, is to present “Site...

2014-10-20 08:32:21

Expands rHuPH20 Production SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract manufacturing facilities used in the production of Hylenex(®) recombinant (hyaluronidase human injection). The FDA approved the use of the Cook Pharmica manufacturing facility in Bloomington, Indiana for the production of bulk rHuPH20, the active ingredient used in Hylenex, and the...

2014-10-20 08:31:57

SAN DIEGO, Oct. 20, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced the appointment of Marco Londei, M.D. as Chief Development Officer. Dr. Londei will lead the preclinical and clinical development of AnaptysBio's proprietary antibody pipeline. http://photos.prnewswire.com/prnvar/20111205/SF16052LOGO "We are pleased to welcome Dr. Londei to AnaptysBio's executive leadership team," said Hamza Suria,...

2014-10-20 08:27:27

NEW YORK, Oct. 20, 2014 /PRNewswire/ -- Mapp Biopharmaceutical's valiant effort to produce more of their experimental ZMapp(TM) antibody therapeutic to fight the Ebola outbreak will make the public aware of how difficult and time-consuming the production of pharmaceuticals can be, according to Kalorama Information. The healthcare market research publisher said that while some may be taken aback by the three-month production cycle of this compound, those with industry knowledge are...

2014-10-17 08:25:39

BEIJING, Oct. 17, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has received approval from the China Food and Drug Administration (the "CFDA") for commercial manufacturing of human prothrombin complex concentrate ("PCC") at its Shandong Taibang facility. The CFDA inspected Shandong Taibang's new coagulation factor...

2014-10-16 08:30:28

ST. LOUIS, Oct. 16, 2014 /PRNewswire/ -- BioReliance(®) (www.bioreliance.com), Sigma-Aldrich Corporation's (NASDAQ: SIAL) biologics and early-development services business under SAFC(®) Commercial (www.sigmaaldrich.com/safc), has introduced select in vitro ADME (absorption, distribution, metabolism and excretion) and toxicology testing services for pharmaceutical, chemical and industrial consumer products to its service offering. The broad set of highly predictive assays use a novel...

2014-10-15 16:30:17

Introduces Chairman Gewanter, shows support for BQ proposal GENEVA, Oct. 15, 2014 /PRNewswire/ -- The Alliance for Safe Biologic Medicines (ASBM) presented at the World Health Organization's (WHO) 59(th) International Nonproprietary Naming Stakeholders Session on Tuesday, October 14, 2014. This was the third time ASBM presented to the WHO but the first appearance for ASBM's new chairman Dr. Harry L. Gewanter. As a practicing pediatric rheumatologist and ASBM International Advisory...

2014-10-15 08:29:01

-- Mark Pimentel, M.D., FRCP(C), of Cedars-Sinai Medical Center Serves as Chairman -- ROCKVILLE, Md., Oct. 15, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, announced today the expansion of its Clinical Advisory Board (CAB) created to support development of SYN-010, the Company's statin-class candidate intended to...

2014-10-14 23:09:20

Selexis has promoted director of European business development, Marco Bocci, PhD, PharmD, to Vice President, European Licensing and Business Development for Europe. Geneva, Switzerland (PRWEB) October 14, 2014 Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development, has promoted director of European business development, Marco Bocci, PhD, PharmD, to Vice President, European Licensing and Business Development. Bocci...


Word of the Day
ween
  • To think; to imagine; to fancy.
  • To be of opinion; have the notion; think; imagine; suppose.
The word 'ween' comes from Middle English wene, from Old English wēn, wēna ("hope, weening, expectation"), from Proto-Germanic *wēniz, *wēnōn (“hope, expectation”), from Proto-Indo-European *wen- (“to strive, love, want, reach, win”).
Related